BioCardia, Inc (BCDA)

Etorro trading 970x250
BioCardia, Inc (BCDA) Logo

About BioCardia, Inc

BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia. The company is also developing CardiALLO Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California. Address: 125 Shoreway Road, San Carlos, CA, United States, 94070

BioCardia, Inc News and around…

Latest news about BioCardia, Inc (BCDA) common stock and company :

BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference
10 Jan, 2022 Yahoo! Finance

SUNNYVALE, Calif. , Jan. 10, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and respiratory diseases, today announced it will be delivering virtual presentations during two investor meetings: The H.C. Wainwright BioConnect Virtual Conference taking place on January 10-13The Biotech Showcase taking place January 10-12 Dr. Peter Altman and Mr. David McClung, CEO and CFO of BioCardi

Alzheimer’s Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases
05 Jan, 2022 FinancialContent
12 Health Care Stocks Moving In Monday's Pre-Market Session
27 Dec, 2021 FinancialContent

Gainers Microbot Medical (NASDAQ:MBOT) stock moved upwards by 55.35% to $8.42 during Monday's pre-market session. ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
23 Dec, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! Christmas is almost here but were aren't slowing down as we dive into the biggest pre-market stock movers for Thursday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.” #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First...

12 Health Care Stocks Moving In Wednesday's After-Market Session
22 Dec, 2021 FinancialContent

Gainers BioCardia (NASDAQ:BCDA) shares rose 29.91% to $2.91 during Wednesday's after-market session. At the close, BioCardia's ...

Benzinga's Top Ratings Upgrades, Downgrades For December 20, 2021
20 Dec, 2021 FinancialContent

Upgrades According to Keefe, Bruyette & Woods, the prior rating for Old National Bancorp (NASDAQ:ONB) was changed from ...

H.C. Wainwright Sees Over 400% Upside For BioCardia Stock
20 Dec, 2021 FinancialContent

H.C. Wainwrighthasinitiated coverageofBioCardia Inc(NASDAQ: BCDA) with a Buy rating and a $9 price target, ...

BioCardia Establishes New Manufacturing Facility to Enable Its Cell Therapy Product Candidates
15 Dec, 2021 Yahoo! Finance

Facility Being Built Out to Support CardiAMP Cell Therapy Systems, Allogeneic NK1R+ MSC and Biotherapeutic Delivery Device Manufacturing for Clinical Trials of Multiple Programs and Early Commercial ActivitiesSAN CARLOS, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that it has entered into a long-term lease for a new facility in Sunnyvale,

12 Health Care Stocks Moving In Thursday's Pre-Market Session
02 Dec, 2021 FinancialContent

Gainers Omeros (NASDAQ:OMER) stock increased by 15.68% to $7.89 during Thursday's pre-market session. The market ...

Sum Up The Parts: IWC Could Be Worth $204
01 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $203.52 per unit.

BioCardia Reports Third Quarter 2021 Financial Results and Business Highlights
10 Nov, 2021 Yahoo! Finance

SAN CARLOS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the third quarter of 2021 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2021 with the Securities and Exchange Commission. Q3 and Recent Business Highlights: CardiAMP® Cell Therapy for ischemic heart failure (BCDA-01

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance
10 Nov, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus MorphoSys COO To Leave To ...

BioCardia To Release Third Quarter 2021 Financial Results November 10, 2021
08 Nov, 2021 Yahoo! Finance

SAN CARLOS, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it will release third quarter 2021 financial results on Wednesday, November 10, 2021 at 4:30PM ET. About BioCardia®BioCardia, Inc., headquartered in San Carlos, California, is a developer of two biotherapeutic platforms – the CardiAMP autologous bone marrow derived m

Will BioCardia, Inc. (BCDA) Report Negative Q3 Earnings? What You Should Know
02 Nov, 2021 Yahoo! Finance

BioCardia, Inc. (BCDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia
21 Oct, 2021 Yahoo! Finance

SAN CARLOS, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the treatment of the first patient in its Phase III pivotal CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial for patients with no option chronic myocardial ischemia with refractory angina. These patients experience frequent angina (chest pain) attacks that are

BioCardia Issued New U.S. Patent for Technology that Enhances Control for Interventional Catheter Based Therapies
12 Oct, 2021 Yahoo! Finance

Technology Anticipated to Impact Cardiac Biologic Therapies, Transseptal Cardiac Procedures, and Other Interventional Catheter Based TherapiesSAN CARLOS, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of U.S. Patent No: 11,141,568 for “Multi Directional Steerable Catheter” that further protects the Helix™ Biothe

BioCardia Announces First Cross-Over Patient Treated in CardiAMP Cell Therapy Heart Failure Trial
07 Oct, 2021 Yahoo! Finance

SAN CARLOS, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA] a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the treatment of the first cross-over patient in the ongoing Phase III Pivotal CardiAMP® Cell Therapy in Heart Failure Trial for the treatment of ischemic heart failure. A cross-over patient is one who was previously in the control group of the study, has completed f

BioCardia Announces Participation at the A.G.P. Biotech & Specialty Pharma Conference October 13, 2021 (Virtual Conference)
06 Oct, 2021 Yahoo! Finance

SAN CARLOS, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA), a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular diseases, today announced it will be participating in the A.G.P Biotech & Specialty Pharma Conference taking place virtually on October 13, 2021. Dr. Peter Altman, CEO of BioCardia, will be participating in one-on-one meetings at the conference. If you are an institutional or retail investor, and would li

Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation
28 Sep, 2021 Yahoo! Finance

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

50 Biggest Movers From Yesterday
23 Sep, 2021 FinancialContent

Gainers Marin Software Incorporated (NASDAQ: MRIN) shares jumped 61.9% to close at $9.21 on Wednesday following an announcement ...

Why BioCardia's Stock Is Trading Higher Today
22 Sep, 2021 FinancialContent

BioCardia, Inc.(NASDAQ:BCDA)shares are trading higher after Roumell Asset Management reported in a 13D filing a 5.6% stake ...

32 Stocks Moving In Wednesday's Mid-Day Session
22 Sep, 2021 FinancialContent

Gainers Marin Software Incorporated (NASDAQ: MRIN) shares climbed 53.1% to $8.71 following an announcement from management that ...

CardiAMP Cell Therapy Heart Failure Trial to be Featured in Two Presentations at Heart Failure Society of America Annual Meeting 2021
10 Sep, 2021 FinancialContent
BioCardia Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (Virtual Conference)
09 Sep, 2021 FinancialContent
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
01 Sep, 2021 FinancialContent

Gainers GBS (NASDAQ:GBS) stock moved upwards by 51.23% to $4.9 during Wednesday's pre-market session. The market ...

Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021
16 Aug, 2021 FinancialContent
BioCardia to Participate in Upcoming Investor Conferences
13 Aug, 2021 FinancialContent
BioCardia, Inc. (BCDA) Reports Q2 Loss, Tops Revenue Estimates
12 Aug, 2021 Yahoo! Finance

BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of 4.76% and 72.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

BioCardia Reports Second Quarter 2021 Financial Results and Business Highlights
12 Aug, 2021 FinancialContent
Will BioCardia, Inc. (BCDA) Report Negative Q2 Earnings? What You Should Know
05 Aug, 2021 Yahoo! Finance

BioCardia, Inc. (BCDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioCardia, Inc (BCDA) is a NASDAQ Common Stock listed in , ,

970x250